Cannabis Sativa Inc (CBDS)

[JoeHemp]

Dr. Sanjay Gupta disses DEA decision - saying that the permitted marijuana research will result in misleading info (as usual). The targeted beneficiaries of the DEA denial of reclassification will be big pharma (who are already positioning). Small companies will be the ones leading the fight for equity and the CBDS board is built to do just that. Below is a link to Gupta's article on CNN:

Gupta: DEA's missed opportunity on medical marijuana "(CNN)

There is really just one salient question when it comes to today's decision by the Drug Enforcement Administration to expand the number of growers of research-grade marijuana while still not changing the scheduling of marijuana: Will this decision make it significantly easier for scientists to study the medical benefits of marijuana?

The answer sadly is: unlikely. And this is a missed opportunity that could further delay potential therapies to countless people.